Cancer Research UK spinoff raises $41M+ in Series B injection
The estrogen receptor (ER) — which is inhibited by targeted drugs such as the hormone therapy tamoxifen and aromatase inhibitors — is a transcription factor implicated in 75% of breast cancers. Research from Cambridge University suggests that the DNA interactions and transcriptional scope of ER rely on a protein that plays a key role in determining tumor growth and progression — even when resistance to existing drugs has built up.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
